Notwithstanding promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis website (hATTR), is facing significant difficulty from managed care entities. Such insurers are frequently erecting obstacles to reimbursement, like significant expense criteria and approval processes that limit user oppo